康宁杰瑞制药-B(09966)今日盘中大幅下跌7.29%,报收2.33港元。跌势或与公司今日公布其新药JSKN003的两项最新临床研究数据有关。
公司宣布,其在2024年欧洲肿瘤内科学会(ESMO)大会上公布了JSKN003(一种HER2靶向抗体偶联药物)治疗铂耐药卵巢癌患者,以及治疗晚期HER2阳性(IHC 3+)实体瘤(乳腺癌除外)患者的两项临床研究结果。
数据显示,在铂耐药卵巢癌患者中,JSKN003的客观缓解率为56.8%。而在晚期HER2阳性实体瘤患者中,JSKN003的客观缓解率和疾病控制率分别为75.0%和89.3%。总体而言,JSKN003显示出良好的安全性和疗效。但暂时未透露这一新药能否获批上市的时间表,市场存在一定失望情绪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.